Holen Sie sich die Stockscreener-App
9.29
5.69%
0.50
Schlusskurs vom Vortag:
$8.79
Offen:
$8.91
24-Stunden-Volumen:
814.91K
Relative Volume:
0.78
Marktkapitalisierung:
$562.88M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.7152
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
-8.02%
1M Leistung:
-3.43%
6M Leistung:
-29.94%
1J Leistung:
-31.44%
1-Tages-Spanne:
$8.91
$9.61
1-Wochen-Bereich:
$8.65
$10.38
52-Wochen-Spanne:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.29 | 532.59M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Can Ginkgo Bioworks Holdings Inc. stock deliver surprise earnings beat2025 Institutional Moves & Technical Pattern Recognition Alerts - mfd.ru
Ginkgo Bioworks (NYSE:DNA) Shares Up 7.8%Should You Buy? - MarketBeat
What are the future prospects of Ginkgo Bioworks Holdings Inc.July 2025 Opening Moves & Target Return Focused Stock Picks - mfd.ru
Allianz Asset Management GmbH Buys Shares of 192,160 Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Baillie Gifford Reduces Stake in Ginkgo Bioworks Holdings Inc - GuruFocus
Analyst Calls: How cyclical is Ginkgo Bioworks Holdings Incs revenue streamGlobal Markets & Intraday High Probability Alerts - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Ginkgo Bioworks (NYSE:DNA) Shares Down 5.3%What's Next? - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners may be pleased with recent gains after 29% loss over the past year - simplywall.st
Understanding Momentum Shifts in (DNA) - Stock Traders Daily
Ginkgo Bioworks (NYSE:DNA) Trading Up 19.3%Here's What Happened - MarketBeat
Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark - Investing News Network
Ginkgo Bioworks and OpenAI Collaborate on Autonomous Biological Experiments - Intellectia AI
Ginkgo Bioworks' Autonomous Laboratory Driven by Openai's GPT-5 Achieves 40% Improvement over State-Of-The-Art Scientific Benchmark - marketscreener.com
GinkgoOpenAI tie-up cuts protein synthesis cost (DNA:NYSE) - Seeking Alpha
Ginkgo Bioworks stock rises after AI lab collaboration with OpenAI shows 40% cost reduction - Investing.com Canada
Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark – Company AnnouncementFT.com - Financial Times
GPT-5 lab runs 36,000 experiments, cuts protein costs 40% - Stock Titan
Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today - Yahoo Finance
Ginkgo Bioworks announces CFO transition - MSN
Panic Selling: Can Ginkgo Bioworks Holdings Inc maintain sales growthTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Risks Report: How cyclical is Ginkgo Bioworks Holdings Incs revenue streamPortfolio Update Report & High Conviction Investment Ideas - baoquankhu1.vn
Portfolio Update: Can PPTA outperform under higher oil pricesRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Potential Upside Amidst Volatile Valuation - DirectorsTalk Interviews
Ginkgo Bioworks Holdings, Inc. (DNA) Declines More Than Market: Some Information for Investors - sharewise.com
Targets Report: Is Ginkgo Bioworks Holdings Inc a cyclical or defensive stockIPO Watch & Safe Capital Growth Tips - baoquankhu1.vn
Is Ginkgo Bioworks Holdings Inc. a cyclical or defensive stockQuarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru
Bearish Setup: What are the future prospects of Ginkgo Bioworks Holdings IncJuly 2025 Price Swings & Safe Capital Investment Plans - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. (DNA) stock drops despite market gains: Important facts to note - MSN
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 12.2%Here's What Happened - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Trading Down 8.8%Time to Sell? - MarketBeat
Portfolio Recap: Will Ginkgo Bioworks Holdings Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly High Return Stock Opportunities - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY: DNA - FinancialContent
Discipline and Rules-Based Execution in DNA Response - Stock Traders Daily
Portfolio Update: Why is Ginkgo Bioworks Holdings Inc stock going upWeekly Earnings Recap & Safe Capital Growth Tips - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. (DNA) Increases Despite Market Slip: Here's What You Need to Know - sharewise.com
Aug Sentiment: Why is Ginkgo Bioworks Holdings Inc stock going upMarket Growth Review & Target Return Focused Picks - baoquankhu1.vn
Twist Bioscience and Ginkgo Bioworks update 2022 partnership - MSN
Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Exit Recap: Will Ginkgo Bioworks Holdings Inc. stock recover faster than marketWeekly Trading Summary & Fast Gain Swing Alerts - Bộ Nội Vụ
Why The Narrative Around Ginkgo Bioworks Holdings (DNA) Is Shifting After New Fair Value Reset - Yahoo Finance
Why hedge funds are buying Ginkgo Bioworks Holdings Inc. stock2025 Investor Takeaways & Technical Pattern Alert System - Улправда
Ginkgo Bioworks Holdings, Inc. (DNA) rises as market takes a dip: Key facts - MSN
Can Ginkgo Bioworks Holdings Inc. stock beat analyst upgradesPortfolio Gains Report & Growth Focused Entry Point Reports - Улправда
Is Ginkgo Bioworks Holdings Inc. stock overvalued by current metricsQuarterly Growth Report & Community Trade Idea Sharing - Улправда
Ginkgo Bioworks Holdings, Inc. (DNA) stock dips while market gains: Key facts - MSN
Can Ginkgo Bioworks Holdings Inc. Class stock surprise markets with earnings2025 Analyst Calls & Growth Focused Stock Pick Reports - Улправда
How rising interest rates impact Ginkgo Bioworks Holdings Inc. stock2025 Macro Impact & AI Enhanced Market Trend Forecasts - Улправда
Bull Bear: How Ginkgo Bioworks Holdings Inc. stock trades before earningsEarnings Trend Report & Weekly High Potential Alerts - Улправда
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - sharewise.com
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):